Efficacy and Safety of Jiangzhi Tongmai Capsule for the Treatment of Dyslipidemia:a Meta-analysis
Objective:To assess the clinical effectiveness and safety of Jiangzhi Tongmai Capsule for the treatment of dyslipidemia.Methods:VIP,China National Knowledge Infrastructure(CNKI),WanFang Data,China Biology Medicine Disc(CBM),PubMed,the Cochrane Library,and EMbase were searched for randomized controlled trials(RCT)of Jiangzhi Tongmai Capsule for the management of dyslipidemia.The retrieval time limit is from the establishment of the databases to September 2022.The Cochrane systematic review manual bias risk assessment tool was used to evaluate the bias risk of the included study.The Stata 14.0 software was used for Meta analysis.Results:A total of 11 RCT were included,involving 914 cases.Meta-analysis showed that total cholesterol(TC)(MD=-0.69,95%CI-0.98--0.40,P<0.00001),low density lipoprotein cholesterol(LDL-C)(MD=-0.52,95%CI-0.74--0.31,P<0.00001),triglyceride(TG)(MD=-0.47,95%CI-0.67--0.26,P<0.00001),carotid intima-media thickness(IMT)(MD=-0.27,95%CI-0.33--0.22,P<0.00001),and carotid plaque score(MD=-1.43,95%CI-2.33--0.63,P =0.0004)in experimental group were lower than those in control group.The high density lipoprotein cholesterol(HDL-C)(MD=0.20,95%CI 0.07-0.32,P=0.002)and clinical efficacy(OR=3.49,95%CI 2.11-5.76,P<0.00001)in experimental group were higher than those in control group.There was no statistically significant difference in the occurrence of adverse reactions between the experimental and control groups(OR=1.25,95%CI 0.59-2.65,P =0.57).Conclusion:Available evidence indicates that combined application of Jiangzhi Tongmai Capsule is superior to conventional western medicine alone in improving the clinical efficacy of dyslipidemia.
万方数据
维普
